DiaSorin's 4% Q2 Growth Came Back - But China, Tariffs, and Margins Keep the Risk Real

Q2 growth improved, but the market is still waiting for proof

This report matters because DiaSorin finally has a why-now catalyst: Q2 2026 revenue up 4% at CER. After a weak start to the year, that rebound suggests the slowdown was not just a one-quarter blip. The question now is whether this is the start of a durable recovery or a short-lived bounce.

Management linked the improvement to strong U.S. performance and normalization after Q1 disruptions. If that U.S. engine keeps healing, the story shifts from relief to rebuild.

That caution is justified by the broader half-year picture. H1 revenue was €602 million, flat at CER and down 3% at current rates, while adjusted net profit fell to €106 million, down 15% year over year. Adjusted EBITDA margin for H1 was 32%, pressured by China pricing challenges and higher U.S. commercial spending. For now, this looks more like a watchlist recovery than an obvious relief trade.

What is driving DiaSorin's rebound

Core U.S. businesses are improving

The mix in Q2 supports the idea that the recovery has real operating breadth. In Q2, immunodiagnostics reached €223 million and grew 4%, licensed technologies reached €43 million and grew 7%, and molecular diagnostics reached €48 million and grew 1%, all at CER.

The clearest signal is in the U.S. immunodiagnostics platform. Management said it returned to historical double-digit growth, helped by the recovery in QuantiFERON sales and an ongoing hospital strategy targeting 600 hospitals by the end of 2026. That is the kind of recovery investors want to see: more instruments in higher-value sites, followed by sustained test volume over time.

New products are also helping. The Liaison Plex platform has more than 150 customers, and the vast majority of new placements chose the Flex configuration. FDA clearance for the second NES assay completed the panel and opened the way to commercialization, with no current pricing pressure observed in the U.S. market. That gives DiaSorin a product-led reason to be more constructive than it was a quarter ago.

Margins still show the rebuild is unfinished

The margin picture explains why the market has not fully celebrated. Gross margin held at 65%, which suggests product economics are still intact. But adjusted EBIT fell 10% at CER, and adjusted EBITDA margin was 32% for the first half. In other words, DiaSorin is spending to rebuild commercial momentum before that spending fully translates into operating leverage.

If growth strengthens and the margin profile improves, that spending can look productive. If spending stays elevated while growth remains modest, investors may see a slow grind instead of a rerating.

China, the Middle East, and tariffs still cap the upside

Geography remains the main risk factor. DiaSorin's first-half growth was driven by the U.S. and Europe, while China and the Middle East continued to weigh on results. Management said China is still declining roughly 25% because of VBP pricing and local competition, with no expected improvement in H2. The Middle East remains damaged as well, with Iran falling from more than €1.5 million to zero, a hit expected through 2026.

Tariffs are another overhang. The company said U.S. tariffs are creating roughly €3 million per quarter of pressure, while it has received only €2.5 million in refunds so far, with no clarity on when the remainder will be recovered.

What would strengthen the case from here

One bridge sentence: the rebound looks real enough to monitor closely, but this is still a watchlist name, not a chase.

Management's full-year guidance is the next reset

Investors will now focus on whether DiaSorin can defend its full-year 2026 guidance for revenue growth and adjusted EBITDA margin of 32%-33%. That matters more than another isolated quarter because management has already defined what "on track" should look like. If guidance holds while growth remains positive, the market can start to treat this as a genuine rebuild. If guidance slips, the pressure likely looks broader than a Q1 hangover.

The clearest signposts are operational

The most useful checkpoints are not narrative-driven: - Watch whether 600 hospitals by end of 2026 keeps becoming reality, because that is the clearest bridge from analyzer placements into future test volume. - Watch whether LIAISON PLEX traction with more than 150 customers turns into repeat demand rather than early excitement alone. - Watch whether molecular diagnostics accelerates in H2, which would show the portfolio is broadening beyond immunodiagnostics.

Why the dividend matters

Management also proposed €1.30 per share, up 8.3%. That does not prove the turnaround, but it does suggest leadership still sees enough earnings and cash generation to increase the payout. In a rebuild story, that is a useful confidence signal.

For now, the practical stance is progress with conditions: Q2 growth is a positive step, but a stronger investor response likely needs better margin proof, cleaner tariff recovery, and fewer headwinds from China.